AgeX Therapeutics Ceo Michael D. West To Participate In Fireside Chat With J. Craig Venter At The Cell & Gene Therapy Ceo Forum

September 21, 2017

ALAMEDA, Calif.–(BUSINESS WIRE)–AgeX Therapeutics, Inc. (AgeX), a subsidiary of BioTime, Inc. (NYSE American: BTX), announces that Chief Executive Officer Michael D. West, Ph.D., who also serves as Co-CEO of BioTime, is participating in a fireside chat at Cell & Gene Therapy CEO on Monday, September 25, 2017 in Boston.

Dr. West’s fireside chat will be at 3:00pm ET/12:00pm PT with J. Craig Venter, Ph.D., Co-Founder and Executive Chairman of Human Longevity, Inc. and founder of Celera Genomics and the J. Craig Venter Institute. It will be moderated by David Grainger, Ph.D., CEO of Methuselah Health and Partner at Medicxi.

Cell & Gene Therapy CEO is an off-the-record networking forum that brings together CEOs and decision makers in cell therapy, gene therapy, and regenerative medicine. Intimate discussion panels, keynotes and fireside chats feature thought leaders debating business model efficiencies, financing, regulatory issues, market access and reimbursement, novel partnerships, manufacturing, and delivery challenges. Healthcare investors and leading researchers also participate.

About AgeX Therapeutics

AgeX Therapeutics, Inc., a subsidiary of BioTime, Inc. (NYSE American: BTX), is a biotechnology company applying technology relating to cellular immortality and regenerative biology to aging and age-related diseases. The company has three initial areas of product development: pluripotent stem cell-derived brown adipocytes (AGEX-BAT1); vascular progenitors (AGEX-VASC1); and induced Tissue Regeneration (iTR). Initial planned indications for these products are Type 2 diabetes, cardiac ischemia, and cancer respectively. More information on AgeX can be found on the company’s website at

About BioTime, Inc.

BioTime is a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases. The Company’s current clinical programs are targeting three primary sectors, aesthetics, ophthalmology and cell/drug delivery. Its clinical programs are based on two platform technologies: pluripotent cells and cell/drug delivery. The foundation of BioTime’s core therapeutic technology platform is pluripotent cells that are capable of becoming any of the cell types in the human body. The foundation of the Company’s cell delivery platform is its HyStem® cell and drug delivery matrix technology. BioTime also has significant equity holdings in two publicly traded companies, Asterias Biotherapeutics, Inc. and OncoCyte Corporation, and one private company, AgeX Therapeutics.

BioTime common stock is traded on the NYSE American and TASE under the symbol BTX. For more information, please visit or connect with the company on TwitterLinkedInFacebookYouTube, and Google+.

To receive ongoing BioTime corporate communications, please click on the following link to join the Company’s email alert list:


Investor Contact:
David Nakasone, 510-871-4188


Media Contact for AgeX:
Gotham Communications, LLC
Bill Douglass, 646-504-0890

See Original Article